Vital Signs - Competitive Bidding - Chaos and Confusion


USD 1,500.00

* Required Fields

USD 1,500.00


Be the first to review this product

This issue of Vital Signs, released on June 4, 2007, provides an strategic overview of the state of the industry in the wake of competitive bidding in Medicare. Additionally, a company profile is provided for Genzyme, a leader in biotechnology. Reimbursement and regulatory news from the FDA is also provided for May 21 - May 25, 2007.

Table of Contents

Vital Signs - Competitive Bidding - Chaos and ConfusionVital Signs: 4 June 2007This week's issue:

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.